Table 1 Characteristics of reports from the FAERS database (January 2012 to December 2022)
|  | Pertuzumab, N (%) |
|---|---|
Gender | Â |
 Female | 12,903 (87.7) |
 Male | 246 (1.7) |
 Unknown | 1558 |
Age | Â |
 Median (Q1,Q3) | 56.4 (48,65) |
Country of the report | Â |
 United States | 4696 (31.9) |
 Canada | 1574 (10.7) |
 Germany | 1360 (9.2) |
 China | 870 (5.9) |
 Great Britain | 839 (5.7) |
Reporter | Â |
 Physician | 7408 (50.4) |
 Consumer | 2583 (17.6) |
 Other health-professional | 1703 (11.6) |
 Pharmacist | 1293 (8.8) |
Indications | Â |
 Breast cancer | 5682 (38.6) |
 HER-2 positive breast cancer | 3238 (22.0) |
 Breast cancer metastatic | 2159 (14.9) |
 Invasive ductal breast carcinoma | 226 (1.5) |
 Premedication | 216 (1.5) |
Outcome | Â |
 Other Serious (Improtant Medical Event) | 2247 (15.3) |
 Hospitalization-Initial or Prolonged | 1787 (12.2) |
 Death | 630 (4.3) |
 Life-Threatening | 250 (1.7) |
 Disability | 70 (0.5) |
Reporting year (5 years) | Â |
 2022 | 2673 |
 2021 | 2615 |
 2020 | 2107 |
 2019 | 1650 |
 2018 | 1537 |